Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials

Paul Jones, Edward Kerwin, Eric Bateman, Rosa Lamarca, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal 2012 40: P2891; DOI:
Paul Jones
1Division of Clinical Sciences, St. George's University, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Kerwin
2Clinical Research Institute, Medford, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Bateman
3Respiratory Medicine, University of Cape Town Lung Institute, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Lamarca
4Clinical Statistics, Almirall, S.A., Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Caracta
5Clinical Development, Forest Research Institute, Jersey City, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Garcia Gil
6R&D Centre, Almirall, S.A., Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

INTRODUCTION:

Aclidinium is a novel, long-acting muscarinic antagonist in development for COPD treatment. Pooled analyses of dyspnea and health status data are shown here.

METHODS:

Patients (N=1389) were randomized (1:1:1) to aclidinium 200 μg, 400 μg or pbo BID for 12- and 24-weeks for the ACCORD and ATTAIN trials, respectively. Endpoints for both studies included TDI focal score, SGRQ total score and rescue medication use.

RESULTS:

The 200 μg and 400 μg groups showed statistically significant improvements from baseline to Week 12 in TDI focal score vs pbo (200 μg, 0.58, p<0.01; 400 μg, 0.92, p<0.0001), with numerically greater improvements seen with the higher dose. Clinically significant improvements (≥1-unit increase) in TDI at Week 12 were seen in a significantly higher proportion of patients in the 200 μg (51.3%, p=0.0001) and 400 μg (54.8%, p<0.0001) groups vs pbo (38.8%). Both doses resulted in statistically significant improvements from baseline to Week 12 in SGRQ total score vs pbo (200 μg, -5.10; 400 μg, -5.51, both p<0.0001). Clinically significant improvements (≥4-unit decrease) in SGRQ total score were seen in a significantly higher percentage of patients in the 200 μg (51.0%) and 400 μg (51.8%) groups (both p<0.001) vs pbo (38.1%) at Week 12. Both doses of aclidinium resulted in a significant reduction over pbo in daily rescue medication use (-0.6 puffs, 200 µg; -0.9 puffs, 400 µg; both p<0.005).

CONCLUSIONS:

Aclidinium 200 μg and 400 μg BID resulted in significantly more COPD patients who experienced clinically meaningful benefits in dyspnea and health status (>12% more in every case) as well as less rescue medication use versus placebo.

  • COPD - management
  • Bronchodilators
  • Quality of life
  • © 2012 ERS
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials
Paul Jones, Edward Kerwin, Eric Bateman, Rosa Lamarca, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2891;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials
Paul Jones, Edward Kerwin, Eric Bateman, Rosa Lamarca, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2891;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
  • Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
  • Increased expression of ADRB2, CHRM3 and glucocorticoid alpha receptor genes in blood leukocytes of COPD patients
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society